Literature DB >> 15082610

Diagnostic utility of reflux disease symptoms.

M Shaw1.   

Abstract

Symptom assessment, by structured interview or questionnaire, is central to the diagnosis of gastro-oesophageal reflux disease (GORD). However, empiric support for the diagnostic utility of reflux symptom measures is lacking. Reliable reflux symptom questionnaires have been developed with content validity. These questionnaires need to be evaluated in terms of diagnostic accuracy, support for application of specific treatment, and improved outcomes resulting from their use. The impact on clinical outcomes of GORD diagnosis by valid questionnaires or structured interview has not been studied.

Entities:  

Mesh:

Year:  2004        PMID: 15082610      PMCID: PMC1867780          DOI: 10.1136/gut.2003.034280

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

1.  Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease.

Authors:  M J Shaw; N J Talley; T J Beebe; T Rockwood; R Carlsson; S Adlis; A M Fendrick; R Jones; J Dent; P Bytzer
Journal:  Am J Gastroenterol       Date:  2001-01       Impact factor: 10.864

2.  A new questionnaire for gastroesophageal reflux disease.

Authors:  G R Locke; N J Talley; A L Weaver; A R Zinsmeister
Journal:  Mayo Clin Proc       Date:  1994-06       Impact factor: 7.616

3.  Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease.

Authors:  R Fass; J J Ofman; I M Gralnek; C Johnson; E Camargo; R E Sampliner; M B Fennerty
Journal:  Arch Intern Med       Date:  1999-10-11

4.  The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease.

Authors:  R Carlsson; J Dent; E Bolling-Sternevald; F Johnsson; O Junghard; K Lauritsen; S Riley; L Lundell
Journal:  Scand J Gastroenterol       Date:  1998-10       Impact factor: 2.423

5.  Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies).

Authors:  N J Talley; V Meineche-Schmidt; P Paré; M Duckworth; P Räisänen; A Pap; H Kordecki; V Schmid
Journal:  Aliment Pharmacol Ther       Date:  1998-11       Impact factor: 8.171

6.  Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response.

Authors:  T Lind; T Havelund; R Carlsson; O Anker-Hansen; H Glise; H Hernqvist; O Junghard; K Lauritsen; L Lundell; S A Pedersen; A Stubberöd
Journal:  Scand J Gastroenterol       Date:  1997-10       Impact factor: 2.423

7.  Cimetidine improves GERD symptoms in patients selected by a validated GERD questionnaire.

Authors:  F Johnsson; Y Roth; N E Damgaard Pedersen; B Joelsson
Journal:  Aliment Pharmacol Ther       Date:  1993-02       Impact factor: 8.171

8.  The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain.

Authors:  R Fass; M B Fennerty; J J Ofman; I M Gralnek; C Johnson; E Camargo; R E Sampliner
Journal:  Gastroenterology       Date:  1998-07       Impact factor: 22.682

9.  Symptoms in gastro-oesophageal reflux disease.

Authors:  A G Klauser; N E Schindlbeck; S A Müller-Lissner
Journal:  Lancet       Date:  1990-01-27       Impact factor: 79.321

  9 in total
  9 in total

1.  The value of Carlsson-dent questionnaire in diagnosis of gastroesophageal reflux disease in area with low prevalence of gastroesophageal reflux disease.

Authors:  Nisa Netinatsunton; Siriboon Attasaranya; Bancha Ovartlarnporn; Sulee Sangnil; Sopa Boonviriya; Teerha Piratvisuth
Journal:  J Neurogastroenterol Motil       Date:  2011-04-27       Impact factor: 4.924

2.  Prevalence of acid reflux in functional dyspepsia and its association with symptom profile.

Authors:  J Tack; P Caenepeel; J Arts; K-J Lee; D Sifrim; J Janssens
Journal:  Gut       Date:  2005-06-21       Impact factor: 23.059

3.  Risk factors for gastroesophageal reflux disease, reflux esophagitis and non-erosive reflux disease among Chinese patients undergoing upper gastrointestinal endoscopic examination.

Authors:  Juan Du; Jiang Liu; Hong Zhang; Chao-Hui Yu; You-Ming Li
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

4.  Lack of correlation between a self-administered subjective GERD questionnaire and pathologic GERD diagnosed by 24-h esophageal pH monitoring.

Authors:  Kevin Chan; Geoffrey Liu; Linda Miller; Clement Ma; Wei Xu; Christopher M Schlachta; Gail Darling
Journal:  J Gastrointest Surg       Date:  2010-03       Impact factor: 3.452

5.  Patient or physician - who is able to evaluate gastroesophageal reflux disease symptoms better?

Authors:  Anita Gasiorowska
Journal:  J Neurogastroenterol Motil       Date:  2011-10-31       Impact factor: 4.924

6.  Heartburn or angina? Differentiating gastrointestinal disease in primary care patients presenting with chest pain: a cross sectional diagnostic study.

Authors:  Stefan Bösner; Jörg Haasenritter; Annette Becker; Maren A Hani; Heidi Keller; Andreas C Sönnichsen; Konstantinos Karatolios; Juergen R Schaefer; Erika Baum; Norbert Donner-Banzhoff
Journal:  Int Arch Med       Date:  2009-12-12

7.  Applying data mining techniques in the development of a diagnostics questionnaire for GERD.

Authors:  Noya Horowitz; Menachem Moshkowitz; Zamir Halpern; Moshe Leshno
Journal:  Dig Dis Sci       Date:  2007-04-10       Impact factor: 3.487

8.  Association of esophageal inflammation, obesity and gastroesophageal reflux disease: from FDG PET/CT perspective.

Authors:  Yen-Wen Wu; Ping-Huei Tseng; Yi-Chia Lee; Shan-Ying Wang; Han-Mo Chiu; Chia-Hung Tu; Hsiu-Po Wang; Jaw-Town Lin; Ming-Shiang Wu; Wei-Shiung Yang
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

9.  Associations of Circulating Gut Hormone and Adipocytokine Levels with the Spectrum of Gastroesophageal Reflux Disease.

Authors:  Ping-Huei Tseng; Wei-Shiung Yang; Jyh-Ming Liou; Yi-Chia Lee; Hsiu-Po Wang; Jaw-Town Lin; Ming-Shiang Wu
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.